Background: Despite remarkable results with salvage standard-dose or high-dose chemotherapy 15% of patients with relapsed germ-cell tumors (GCT) are incurable. Immune checkpoint inhibitors have produced significant remission in multiple tumor types. We report the first study of immunotherapy in patients with GCT.
Introduction
Germ-cell tumors (GCT) are remarkably chemosensitive and up to 80% of patients with metastatic disease will be cured with cisplatin-based combination chemotherapy [1] . Patients who relapse after initial chemotherapy can still be cured with salvage therapy including salvage surgery, standard dose chemotherapy, or high-dose chemotherapy plus peripheral-blood stem-cell transplant (PBSCT) [2] [3] [4] [5] [6] [7] . Despite the high cure rates with frontline and salvage chemotherapy, there remains a 15%-20% cohort of patients with metastatic GCT who are incurable with the current therapeutic options. Novel therapeutic approaches are needed for these patients.
Monoclonal antibodies against programmed death 1 (PD-1) and its ligands (PD-L1 and PD-L2) have demonstrated robust activity and manageable toxicity in many advanced tumors including melanoma, lung, kidney, urothelial, and other malignancies [8] [9] [10] [11] . Pembrolizumab is a highly selective, humanized monoclonal IgG4j isotype antibody against PD-1 which can disrupt the engagement of PD-1 with its ligands and impede inhibitory signals in T cells.
Frequent PD-L1 expression has been reported in tumor samples from testicular cancer patients suggesting that these patients could potentially benefit from immunotherapy approaches with PD-1 or PD-L1 inhibition [12] . In addition, a prognostic value has been suggested for PD-L1 expression on testicular GCT indicating that patients with high PD-L1 expression were more likely to have poor clinical features and worse survival outcomes [13] . Case series have been reported regarding possible activity of PD-1 inhibitors in combination with chemotherapy in a small sample of four patients with platinum refractory GCT [14] .
Immune therapy with pembrolizumab is a novel approach for salvage in patients with metastatic GCT. In a multicenter singlearm open-label phase II trial conducted within the Hoosier Cancer Research Network, we evaluated the efficacy and safety of pembrolizumab in patients with refractory GCT with no further curative treatment options.
Patients and methods

Patients
Eligible patients had histologically confirmed metastatic GCT (seminoma or nonseminoma histology) who progressed after first-line cisplatin-based chemotherapy and after at least one salvage regimen: standard-dose chemotherapy or high-dose chemotherapy plus PBSCT. Relapsed patients who are not eligible for salvage chemotherapy (e.g. late relapse of disease) were also included in this study. An Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 was required (on a 5-point scale, with 0 indicating no symptoms and higher numbers indicating greater disability). Patients had measurable metastatic disease according to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1 and/or elevation of tumors markers [alpha-fetoprotein (AFP) and/or b-human chorionic gonadotropin (b-hCG)] [15] . If a rising tumor marker was the only evidence of progressive disease, two consecutive rising values at least 1 week apart were required. Patients with treated brain metastases were eligible. Treatment with systemic corticosteroids or immunosuppressants within 7 days of first trial treatment was not permitted. All patients were required to provide archived tumor tissue from a biopsy or the original primary tumor for PD-L1 expression evaluation and other exploratory analyses. Patients were eligible irrespective of PD-L1 staining result. Patients were ineligible if they had received anti-PD-1 or anti-PD-L1 therapy previously. Full eligibility criteria are listed in the trial protocol (supplementary File S1, available at Annals of Oncology online), available online with the full text of this article.
Pretreatment evaluation
Pretreatment evaluation included complete history and physical examination, performance status, complete blood count, comprehensive metabolic profile, serum tumor markers (AFP and hCG), creatinine clearance, electrocardiogram and computed tomography (CT) scan of the chest, abdomen and pelvis.
Treatment program
Planned treatment consisted of pembrolizumab 200 mg administered intravenously (i.v.) every 3 weeks. Pembrolizumab was provided by Merck & Co., the supporter of this investigator initiated phase II trial. Treatment was continued until documented disease progression, development of unacceptable level of toxic effects, withdrawal of consent, decision by investigator to discontinue treatment or the completion of 52 weeks of pembrolizumab therapy.
Evaluation of response and toxicity
Patients were assessed on day 1 of each 3-week cycle. A complete blood count, complete metabolic panel, and tumor markers were determined on day 1 of each cycle. Toxicities were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0. Tumor imaging was carried out at baseline followed by every 6 weeks for the initial 18 weeks. Subsequently, imaging was spaced to every 12 weeks until discontinuation of study drug. The full assessment schedule is provided in the trial protocol.
PD-L1 expression was assessed in formalin-fixed archived tumor samples at a central laboratory with the use of the commercially available PD-L1 IHC 22C3 assay. PD-L1 expression was scored as 0 (no staining), 1 (weak staining), 2 (moderate staining), 3 (intense staining) along with categorized PD-L1 combined positive score, defined as the percentage of PD-L1-expressing tumor and infiltrating immune cells relative to the total number of tumor cells (H-score).
End points and statistical analysis
The primary end point was overall response rate (ORR) using immune related response criteria (irRC) [16] . Secondary end points were ORR using RECIST version 1.1, to assess toxicity and tolerability of pembrolizumab, and to estimate the duration of disease response [15] . Exploratory objectives included assessment of prevalence of PD-L1 expression in tumor tissue and correlate with tumor response to treatment. Efficacy was assessed in the intention-to-treat population, which included all the patients who were assigned to the treatment group. Safety was assessed in the as-treated population, which included all the patients who received at least one dose of study treatment.
A Simon two-stage optimal design with type I error rate of 20% and power of 80% was utilized [17] . The null hypothesis was an ORR of 10% and the alternate hypothesis was ORR 15%. Consequently, 12 subjects were enrolled in the first stage. If no responses are determined in the initial stage, the study will be concluded. If at least 1 patient achieved a partial or complete response, then the treatment will be considered worthy of further investigation and 8 more subjects will be accrued in the second stage for a total sample size of 20 subjects. If there are three or more subjects with partial or complete response, then the treatment regimen would be considered a success. Statistical analyses were carried out using SAS software, version 9.4. The data cut-off was February 2017. The study schema is depicted in Figure 1 .
Results
Patient and disease characteristics
Twelve patients were enrolled between March and October 2016. Patient characteristics are provided in Table 1 . Median age was 38 years (range 27-55 years) and all patients were male. Primary tumor sites were testis in 11 patients (92%) and mediastinal nonseminoma in 1 patient (8%). All patients had nonseminoma histology. Tumor markers were elevated in all patients: AFP only in three, hCG only in three, both AFP and hCG were elevated in six patients. Metastatic sites included retroperitoneal lymph nodes in five patients, pulmonary metastasis in nine patients, liver metastasis in three patients, brain and bone metastasis in one patient each. The median number of previous chemotherapy lines of treatment was three (range 1-6). Six patients (50%) received prior high-dose chemotherapy and autologous stem-cell transplant as a previous line of therapy. Ten patients had received prior ifosfamide or paclitaxel-containing salvage chemotherapy regimens. Six patients (50%) had late relapse of disease defined as disease that relapsed more than 2 years after first-line cisplatinbased combination chemotherapy.
Treatment administration
All 12 patients enrolled received at least one dose of pembrolizumab 200 mg i.v. per study protocol. The median number of pembrolizumab doses was 2 (range 1-8). Two patients received only one dose of pembrolizumab and had clear clinical disease progression at the time of the scheduled second dose. Eight patients received two doses of pembrolizumab and had disease progression at the 6 week interim evaluation. One patient received six doses and another patient received eight doses of pembrolizumab.
Efficacy
No partial or complete responses were observed. Two patients achieved stable disease for 28 and 19 weeks, respectively. Both these patients had continued rising AFP values on treatment despite radiographic stability. One of these patients had late relapse with no response to previous salvage standard-dose chemotherapy [paclitaxel-ifosfamide-cisplatin (TIP) and paclitaxel-gemcitabine] before enrolling on this clinical trial. The second patient with radiographic stability did not have late relapse of disease and had slow progression after salvage standard-dose chemotherapy with TIP and gemcitabine-oxaliplatin. Ten patients had progressive disease as their best response. None of the patients on study had tumor marker decline while on treatment with pembrolizumab.
Per study protocol, at least 1 objective response was required to continue enrolling on the second stage of the study; therefore, the trial was closed at the completion of the first stage. At last followup, 6 of the 12 patients enrolled had died of disease progression.
Biomarker analysis
Archival formalin-fixed paraffin-embedded tissue samples were available for correlative studies in all patients. Correlative studies were carried out on samples from primary testicular tumor in four patients, retroperitoneal lymph nodes in six patients, bone metastasis biopsy sample in one patient, and lung metastasis biopsy sample in one patient. Immunohistochemistry staining of archival tumor samples was positive for PD-L1 expression in two patients: one patient with predominant embryonal carcinoma histology had 3þ staining in 30% of tumor cells formulating an H-score of 90. Another patient with predominant choriocarcinoma histology had 1þ staining on 50%, 2þ staining on 30% and 3þ staining on 20% of tumor cells formulating an H-score of 170. Both these patients had progressive disease as their best response to therapy.
Toxicity
Pembrolizumab was tolerated by this patient population with six patients experiencing grade 3 adverse events. Four adverse events were possibly related to disease or study treatment. Grade 3 or higher and most commonly occurring adverse events are listed in Table 2 . No grade 4 or 5 toxicities were observed. There were no immune-related adverse events observed.
Discussion
In the current era, cisplatin-based combination chemotherapy will cure >80% of patients with metastatic GCT [18] . A 90% of patients with International Germ-Cell Cancer Collaborative Group (IGCCCG) good-risk disease will achieve cure with frontline chemotherapy. Patients with intermediate and poor-risk disease have less favorable outcomes and a significant proportion will relapse and require salvage therapy [19] . High-dose chemotherapy plus PBSCT achieves cures in 60% of patients with relapsed metastatic GCT [2, 3, 20] . Patients who relapse after salvage standard-dose or high-dose chemotherapy have poor outcomes with no further curative options short of salvage surgery in patients with anatomically localized disease [7, 21] . Understanding the mechanism(s) of resistance to treatment are desperately needed. Unfortunately, early studies with molecularly targeted therapies such as imatinib, sunitinib, thalidomide and trastuzumab have yielded negative results [22] [23] [24] [25] . More recently, studies with pazopanib have provided some signal of activity [26] .
Immunotherapy with PD-1 and PD-L1 inhibitors has demonstrated remarkable results in a variety of advanced solid malignancies after progression on standard-of-care treatment [8] [9] [10] [11] . Preclinical investigations have shown that PD-L1 expression was present in 73% of all seminomas and 64% of nonseminomas [12] . Our study represents the first clinical trial investigating immunotherapy with checkpoint inhibitors as a novel approach in patients with platinum-refractory incurable GCT.
Pembrolizumab was tolerated in this study with no immunerelated adverse events reported. Unfortunately, this clinical trial did not show clinical activity for pembrolizumab in patients with metastatic GCT who progressed after salvage chemotherapy. No objective responses were observed among the 12 patients enrolled; although 2 patients had radiographic stable disease for 28 and 19 weeks, respectively, both had continued rising AFP level during treatment suggesting continued treatment resistance. PD-L1 expression was present on tumor samples from only two patients in this study. Both these patients had progressive disease as their best response.
Although this phase II trial investigated a novel approach for salvage in refractory GCT, there are limitations to report. The small cohort of patients limits the generalizability. Other studies are underway investigating single agent or combination checkpoint inhibition in patients with metastatic GCT. Immunohistochemistry staining for PD-L1 was carried out on archival tumor tissues which may not represent the current immune status or the tumor microenvironment at the time of treatment with checkpoint inhibitor. In addition, PD-L1 expression from tumor metastatic sites was not carried out and this might also be informative. The expression of PD-L1 is known to be dynamic and is regulated by extrinsic signaling such as release of interferon-c by immune cells, loss of expression of tumor suppressor genes or activation of the AKT-mTOR pathway [27, 28] . Moreover, this study was not a biomarker driven study since all patients were eligible irrespective of PD-L1 expression. Higher levels of PD-L1 expression have been associated with robust responses in certain advanced solid tumors such as melanoma and lung cancer but not in others [10, 11] . In addition, the protocol for this study mandated response assessment at 6 weeks, i.e. after two infusions of pembrolizumab at which time most patients had progressive disease. This might have been a short interval given our understanding that the immune checkpoint inhibitors have a median time to response of 2 months [8, 10] . Nevertheless, patients on this study had clinical unequivocal rapid progression while on study treatment. Even though no immune-related adverse events were observed, the short duration of exposure to pembrolizumab with a median number of deliverable doses of two might influence that analysis.
In conclusion, this is the first reported clinical trial evaluating immune checkpoint inhibitors in testicular cancer. Single agent pembrolizumab did not demonstrate clinical benefit in this cohort of patients with refractory GCT. Further investigation requires evaluation of the mechanism of resistance and possible combination therapy.
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